BIOSIG TECHNOLOGIES, INC. BSGM Income Statement

Biosig technologies, inc. (BSGM)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Sep'13	Jun'13
Operating expenses:
Research and development
4,926	4,788	1,643	1,817	1,488	1,312	744	1,449	862	954	1,124	1,339	1,338	568	560	1,153	372	360	354	489	302	181	144	99	122	289	178
General and administrative
7,855	10,429	3,841	6,160	4,378	4,388	2,405	4,314	1,771	4,117	786	1,676	1,557	1,187	991	4,380	1,939	1,724	2,117	3,938	2,746	2,422	3,796	484	601	509	1,041
Depreciation and amortization
21	17	18	9	7	-	2	2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation
-	-	-	-	-	-	-	-	2	2	2	2	3	2	2	2	2	2	2	2	2	3	3	4	4	4	4
Total operating expenses
12,802	15,236	5,503	7,988	5,875	5,705	3,152	5,766	2,637	5,074	1,914	3,018	2,899	1,758	1,554	5,535	2,314	2,088	2,474	4,430	3,051	2,607	3,944	588	728	803	1,224
Loss from operations
-12,802	-15,236	-5,503	-7,988	-5,875	-5,705	-3,152	-5,766	-2,637	-5,074	-1,914	-3,018	-2,899	-1,758	-1,554	-5,535	-2,314	-2,088	-2,474	-4,430	-3,051	-2,607	-3,944	-588	-728	-803	-
Loss from operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,224
Other income (expense):
Gain on change in fair value of derivatives
-	-	-	-	-	-	-	-	0	530	113	-60	-373	384	17	-556	-268	63	2,851	198	0	-	0	0	-	-	-
Interest income, net
39	48	39	39	6	8	1	0	0	0	0	0	0	0	0	0	0	0	0	-0	-1	-1	-0	-7	-1	-0	-0
Gain on disposal of assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-
Financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	529	-	-	-	-	-	-	-
Financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	14	190	388	1,790	-
Total other income (expense)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-268	63	2,851	-331	-1	-	-	-	-	-	-
Total other income (expense)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-15	-198	-	-	-
Financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	614
Loss before income taxes
-12,763	-15,187	-5,464	-7,949	-5,869	-5,696	-3,150	-5,766	-2,637	-4,544	-1,800	-3,078	-3,272	-1,374	-1,537	-6,092	-2,582	-2,024	377	-4,761	-3,052	-2,608	-3,960	-787	-1,117	-2,594	-1,839
Income taxes (benefit)
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net loss
-12,763	-	-5,464	-	-5,869	-	-3,150	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Preferred stock dividend
4	4	4	4	10	104	194	280	305	50	22	22	23	24	24	28	32	107	53	112	79	70	63	83	84	84	75
Net loss attributable to common stockholders
-12,767	-15,192	-5,468	-7,954	-5,880	-5,801	-3,345	-6,047	-2,942	-4,594	-1,822	-3,101	-3,296	-1,399	-1,561	-6,120	-2,615	-2,131	324	-4,873	-3,132	-2,678	-4,023	-870	-1,201	-2,678	-1,914
Non-controlling interest
1,427	-	20	-	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET LOSS ATTRIBUTABLE TO BIOSIG TECHNOLOGIES, INC.
-11,340	-14,801	-5,448	-7,949	-5,880	-6,386	-3,345	-5,766	-2,637	-4,544	-1,800	-3,078	-3,272	-1,374	-1,537	-6,092	-2,582	-2,024	377	-4,761	-3,052	-2,608	-3,960	-787	-1,117	-2,594	-1,839
Net loss per common share, basic and diluted (in Dollars per share)
-0.46	-0.69	-0.25	-0.38	-0.33	-0.50	-0.22	-0.44	-0.09	-0.82	-0.17	-0.12	-0.14	-0.05	-0.08	-0.32	-0.15	-0.11	0.02	-0.35	-0.26	-0.28	-0.39	-0.10	-0.14	-0.33	-0.23
Weighted average number of common shares outstanding, basic and diluted (in Shares)
24,389	22,449	21,809	20,671	17,848	-1,263	15,529	13,807	29,944	-17,730	10,428	25,131	23,051	21,431	20,581	18,875	17,074	15,453	14,849	13,852	12,256	11,117	10,218	8,782	8,482	8,192	8,185